Do you want to read an article? Please log in or register.
Benefits of CMAB007 in Chinese Patients Having Inadequately Controlled Moderate/Severe Asthma With Increased Total IgE: A Randomized Phase 3 Trial
Asthma
Related content
RECOMMENDED
Asthma
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, Cao J, Zhou Q, Howarth P, Weng S, Xiong C, Huang J, Liang P, Zhong N, 201536 Study Group
doi: 10.4168/aair.2025.17.4.473
RECOMMENDED
AsthmaFurther Publications
Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med
Kerwin E, Yang T, Su N, Guo J, Adivikolanu R, Longphre M, Wang J, Yun J, Pan W, Wei Z, Collazo R
doi: 10.1164/rccm.202409-1708OC
RECOMMENDED
Asthma
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Patel C, Sheth V, Koppula R, Kumar A, Bhate AS, Sahoo D, Jain MK, Mondal A, Parmar D, Kansagra K, Shrivastava R, Pathak H
doi: 10.1016/j.rmed.2025.108293
Asthma
Efficacy and Safety of Dupilumab in Children With Moderate-to-Severe Asthma: A Systematic Review of Emerging Phase 3 Evidence
Pediatr Pulmonol
Ghadah A, Aryam A, Shahad A, Hatun A, Amani A, Zinab B, Anoud A, Abdulmajeed A, Tamer A
doi: 10.1002/ppul.71391
COMMENTED
Asthma
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Castro M, Papi A, Porsbjerg C, Lugogo NL, Brightling CE, González-Barcala FJ, Bourdin A, Ostrovskyy M, Staevska M, Chou PC, Duca L, Pereira AM, Fogarty C, Nadama R, Zhang M, Rodrigues A, Soler X, Sacks HJ, Deniz Y, Rowe PJ, de Prado Gómez L, Jacob-Nara JA
doi: 10.1016/S2213-2600(24)00362-X
Asthma
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial
Am J Respir Crit Care Med
Porsbjerg C, Dunican EM, Lugogo NL, Castro M, Papi A, Backer V, Brightling CE, Bourdin A, Virchow JC, Zhang M, Soler X, Rowe PJ, Deniz Y, de Prado Gómez L, Sacks HJ, Jacob-Nara JA
doi: 10.1164/rccm.202410-1894OC
Lung Cancer
LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial
Clin Cancer Res
Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung YH, Ip V, Li G, Graf RP, Ready N
doi: 10.1158/1078-0432.CCR-25-0952
COMMENTED
Respiratory Tract Infection
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW
doi: 10.1016/S2213-2600(25)00287-5
RECOMMENDED
Asthma
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, Lemaire-Paquette S, Ramakrishnan S, Wechsler ME, Brusselle G, Corren J, Hardy J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud A, Santoro E, Compton C, Hardin ME, Holweg CTJ, Subhashini A, Hinks TSC, Beasley RW, Sont JK, Steyerberg EW, Pavord ID, Couillard S
doi: 10.1016/S2213-2600(25)00037-2